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Abstract
Adeno-associated viral (AAV) vectors (serotype 2) efficiently transduce skeletal muscle, and have 
been used as gene delivery vehicles for hemophilia B and for muscular dystrophies in 
experimental animals and humans. Recent reports suggest that AAV vectors based on serotypes 1, 
5, and 7 transduce murine skeletal muscle much more efficiently than AAV-2, with reported 
increases in expression ranging from 2-fold to 1000-fold. We sought to determine whether this 
increased efficacy could be observed in species other than mice. In immunodeficient mice we saw 
10- to 20-fold higher levels of human factor IX (hF.IX) expression at a range of doses, and in 
hemophilic dogs we observed approximately 50-fold higher levels of expression. The increase in 
transgene expression was due partly to higher gene copy number and a larger number of cells 
transduced at each injection site. In all immunocompetent animals injected withAAV-1, inhibitory 
antibodies to F.IX developed, but in immunocompetent mice treated with high doses of vector, 
inhibitory antibodies eventually disappeared. These studies emphasize that the increased efficacy 
of AAV-1 vectors carries a risk of inhibitor formation, and that further studies will be required to 
define doses and treatment regimens that result in tolerance rather than immunity to F.IX.
Introduction
Recombinant adeno-associated viral (AAV) vectors efficiently transduce skeletal muscle, 
liver, and other cell types. AAV vectors derived from serotype 2 have been used in early-
phase clinical studies in patients with cystic fibrosis,1 hemophilia B,2 and limb-girdle 
muscular dystrophy.3 Several groups have shown that other naturally occurring AAV 
serotypes exhibit distinct profiles in terms of tissue tropisms, and it is now well-established 
thatAAV-1, AAV-5, and AAV-7 transduce murine skeletal muscle more efficiently than the 
more widely used serotype AAV-2,4–7 although there is disagreement in the literature about 
the fold improvement in transgene expression with AAV-1. In studies in humans with 
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hemophilia B, we had previously shown that intramuscular injection of AAV-2 based, factor 
IX (F.IX)–expressing vectors at doses up to 2 × 1012 vector genome (vg)/kg was safe and 
well-tolerated. Biopsies of injected muscle provided clear evidence of gene transfer and 
expression, but at the doses tested did not generally result in circulating levels of F.IX more 
than 1%.2 Based on the studies demonstrating superior efficacy in mice,4–7 it has been 
suggested that use of an AAV-1–based vector would improve efficacy of this approach.
We therefore carried out a series of studies in tissue culture, in mice, and in hemophilic dogs 
to assess the safety and efficacy of AAV-1–mediated gene transfer for hemophilia B. We 
first undertook in vitro and murine studies to establish that AAV-1– and AAV-6–based 
vectors yield higher levels of F.IX, and to identify factors that account for this finding. 
AAV-6 is a naturally occurring recombinant between AAV-1 and AAV-26,8 and its 
efficiency in transducing skeletal muscle is not known. We next preparedAAV-1 vectors 
expressing canine F.IX (cF.IX) and injected these at intramuscular sites in dogs with 
hemophilia B arising from a missense mutation.9 At vector doses lower than those used in 
previous studies with AAV-2,10 we saw circulating cF.IX levels in the range of 87 ng/mL to 
104 ng/mL in the first few weeks after injection, but levels fell to zero as inhibitory 
antibodies developed. Previous work by our group had shown that there is a dose-dependent 
increase in the likelihood of inhibitory antibody formation after intramuscular injection of 
AAV-2–cytomegalovirus (CMV)–F.IX in hemophilic dogs.11 The current studies show that 
these antibodies occur at considerably lower doses with AAV-1 vectors and suggest that the 
local levels of F.IX antigen produced are a major determinant of the likelihood of a harmful 
immune response. Additional studies in hemophilic mice demonstrate that injection of very 
high doses of AAV-1–CMV–human (h) F.IX triggers inhibitory antibody formation initially, 
followed by disappearance of inhibitors and long-term expression of hF.IX. Thus, in animals 
that are not tolerant to the transgene product, the superior efficacy of AAV-1 in skeletal 
muscle poses an increased risk of inhibitory antibody formation. Dose of vector and level of 
transgene expression may determine whether antibodies are transient or persistent.
Materials and methods
AAV vector construction and production
Recombinant AAV vectors were produced by triple transfection as previously described.12 
The plasmids expressing canine or human F.IX under the control of the CMV promoter/
enhancer and a second plasmid supplying adenovirus helper functions were identical to 
those described.10,13 A third plasmid containing the AAV-2 rep and cap genes was used to 
produceAAV-2 vectors, whereas a plasmid containing either AAV-1 or AAV-6 cap genes 
and AAV-2 rep gene and inverted terminal repeats was used to produce AAV-1 and AAV-6, 
respectively (Figure 1). AAV vectors were purified by repeated cesium chloride (CsCl) 
density gradient centrifugation and the titer of purified vectors was determined by 
quantitative dot-blot hybridization.12
Cell culture experiments
Human myoblasts were isolated from muscle biopsy samples obtained from healthy 
volunteers and then differentiated to mature myotubes by incubation in culture media 
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containing 10% horse serum. A murine myoblast cell line (American Tissue Culture 
Collection, Manassas, VA) was kept undifferentiated by incubating with 10% fetal bovine 
serum or alternatively, was incubated with 10% horse serum to differentiate to mature 
myotubes. Cells were transduced with AAV–CMV-hF.IX vector at multiplicities of 
infection (MOIs) ranging from 1000 to 40 000 in serum-free media (Opti-MEMI; Life 
Technologies, Gaithersburg, MD), as previously described.14
Animal experiments
All procedures involving mice and dogs were approved by the Institutional Animal Care and 
Use Committee at The Children’s Hospital of Philadelphia or at the University of North 
Carolina at Chapel Hill.
Twenty-four immunodeficient CD4 knockout mice on a C57Bl/6 background (The Jackson 
Laboratories, Bar Harbor, ME) were injected withAAV-1 orAAV-2 vectors encoding hF.IX 
under the control of the CMV promoter/enhancer. Cohorts of 4 mice were injected at 3 
vector doses of AAV-1 or AAV-2: 2 × 1011, 1.2 × 1012, or 4 × 1012 vg/kg. Intramuscular 
injections were distributed into 4 skeletal muscle sites (tibialis anterior and quadriceps 
muscle). Circulating hF.IX antigen levels were measured in plasma samples collected every 
2 weeks from the retro-orbital space using heparinized capillary tubes.
In addition, hemophilia B mice (C57Bl6, n = 10) were injected with AAV1–CMV-hF.IX 
vectors at doses ranging from 6.5 × 1011 vg/kg to 1.6 × 1013 vg/kg. In these experiments, 
F.IX antigen levels, clotting activity, and antibody formation to F.IX were simultaneously 
determined.
To assess T-cell response to skeletal muscle fibers transduced byAAV-1 vectors, additional 
immunocompetent mice (n = 4) were injected with AAV-1–hF.IX at a dose of 4 × 1012 
vg/kg. Mice were killed at day 14 or day 30 following vector administration, and muscle 
tissue was harvested and fixed and stained by hematoxylin and eosin.
Hemophilia B dogs from University of North Carolina at Chapel Hill have a missense 
mutation in the F.IX gene, which results in F.IX antigen and clotting activity levels less than 
1% of normal.9,15–17 The first animal received an intramuscular injection of AAV-1–CMV-
cF.IX at a dose of 1 × 1012 vg/kg distributed into 36 sites (5 × 1011 vg per site). The second 
animal received an intramuscular injection of AAV-1–CMVcF. IX at a dose of 2.4 × 1011 
vg/kg, distributed in 28 sites of 6.8 × 1010 vg per site. Dog 1 received an intravenous 
infusion of cyclophosphamide, 200 mg/m2 to 250 mg/m2, beginning on day 15 after vector 
infusion and continuing weekly for 6 weeks. Dog 2 received cyclophosphamide 1 day prior 
to the day of injection and weekly thereafter up to 6 doses. No plasma infusion was required 
prior to injection.
Serial blood cell counts and biochemical analysis of serum samples for liver and kidney 
function tests, and muscle enzymes were performed as described before.10
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Clotting assays, F.IX antigen, and antibody to F.IX
hF.IX concentration was determined using an enzyme-linked immunosorbent assay (ELISA) 
in which a monoclonal antibody FXC008 (Boehringer Mannheim, Indianapolis, IN) was 
used as a capture antibody at a dilution of 1:500; peroxidase conjugated polyclonal goat 
antihuman F.IX (Affinity Biologicals, Hamilton, ON, Canada) was used as a detecting 
antibody. Canine F.IX concentration was determined using FXC008 as a capture antibody as 
well. A rabbit anti–cF.IX antibody (Affinity Biolabs, Ontario, ON, Canada) was used at a 
dilution of 1:1000 as a secondary antibody, a swine antirabbit immunoglobulin G (IgG) 
peroxidase labeled at a dilution of 1:2000 (Dako, Carpinteria, CA) was used for detection. 
Whole-blood clotting time (WBCT) and the activated partial thromboplastin time (aPTT) 
were determined as previously described.10,18 The WBCT in hemostatically normal dogs 
ranges from 8 to 12 minutes and the aPTT ranges from 18 to 20 seconds. For hemophilic 
dogs the WBCT ranges from 30 to 60 minutes and the aPTT from 50 to 80 seconds. 
Shortening of the WBCT begins with increases in the F.IX levels above 2 ng/mL. Inhibitory 
antibodies to human or canine F.IX were assayed by Bethesda assay. In addition, inhibitory 
or noninhibitory antibodies to F.IX were measured by both a specific ELISA to IgG 
subclasses or by Western blot analysis as described.18,19
Histochemical analysis
Tissue obtained by muscle biopsy was frozen initially in cooled isopentane followed by 
liquid nitrogen. Muscle sections were stained with hematoxylin and eosin for histology. 
Muscle serial cryosections (5 µm–10 µm) were stained for F.IX expression by 
immunofluorescence using a 1:400 dilution of goat anti–hF.IX antibody (Affinity 
Biologicals) followed by antigoat IgG fluorescein–conjugated antibody at a dilution of 1:10 
000 (Dako).
DNA analysis
Genomic DNA was extracted from injected murine muscle, digested with BglII (New 
England Biolabs, Beverly, MA), separated in a 1% agarose gel, and transferred to 
nitrocellulose membrane. Southern blot hybridization was performed using as probe a 0.7-
kilobase (kb) fragment of the CMV enhancer/ promoter. Intensity of bands on 
autoradiographs was quantitated by densitometric scanning of the exposed x-ray film (http://
rsb.info.nih.gov/nih-image/).
Results
In vitro transduction of murine and human skeletal muscle cells by AAV-2–F.IX vectors 
yields higher levels of F.IX than transduction by AAV-1 vectors
Results from triplicate experiments demonstrated that F.IX levels are consistently 2- to 8.9-
fold higher after differentiation to myotubes compared with undifferentiated myoblasts 
(Table 1). In both differentiated and undifferentiated murine C2C12 cells, AAV-2–F.IX 
yielded higher levels of F.IX (2- to 4-fold) compared with AAV-1–F.IX. Similar results 
were observed with normal human myoblasts. In a typical experiment, following 
differentiation to myotubes, cells were transduced at an MOI of 20 000. After 5 days, F.IX 
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levels in conditioned medium averaged 212 ± 28 ng/mL per 48 hours for AAV-2–transduced 
cells and 111 ± 45 ng/mL per 48 hours forAAV-1–transduced cells.
C57Bl/6/CD4 knockout mice were injected at doses ranging from 2 × 1011 vg/kg to 4 × 1012 
vg/kg (n = 4 per group) with AAV vectors.AAV-1 andAAV-6 vectors resulted in 10- to 20-
fold higher levels of circulating F.IX at each dose tested (Figure 2). F.IX levels inAAV-2–
injected mice were generally reproducible (Table 2) with variation among mice being less 
than or equal to 20% at a dose of 1 × 1012 vg/kg, whereas variation was higher among mice 
at low doses of AAV-1 (as much as 50%) and less at higher doses (± 10%). A dose-
dependent increase in levels of F.IX was seen for all doses of AAV-1 and AAV-6 tested 
(Table 2 [AAV-1]; AAV-6, data not shown).
Superior expression from AAV-1 vectors is partly due to higher gene copy number at 
injected sites
Samples of murine muscle tissue injected with a range of doses of AAV-1 orAAV-2 vectors 
were excised 12 weeks after injection and DNA was extracted. Southern blots were 
performed to determine DNA copy number (Figure 3). In these experiments, the dose per 
site is proportional to the dose per kilogram. A copy number standard was prepared by 
spiking AAV vector plasmid into murine DNA. Uncut DNA showed a diffuse high-
molecular-weight signal (data not shown). Restriction digest with BglII produced a fragment 
of approximately 0.7 kb, as expected. Comparison of signal strength showed a higher gene 
copy number in AAV-1–transduced tissue compared with AAV-2–transduced tissue at every 
dose tested. The fold increase in gene copy number is greater at low doses than at higher 
doses (Table 3).
At an equivalent dose per injection site, larger numbers of muscle cells are transduced by 
AAV-1 vectors compared with AAV-2
Mice injected at a dose of approximately 4 × 1012 vg/kg were killed 8 weeks after injection, 
and muscle tissue was excised and stained by immunofluorescence for hF.IX. Two 
technologists blinded to vector type scored positive cells by counting 26 fields in 6 sections. 
Scoring sections from the quadriceps and tibialis anterior, in AAV-1–injected tissue, 54% of 
cells were positive on average (range 38%–67%) and inAAV-2–injected cells, 22% (range 
17%–32%) were positive on average. Representative sections are shown in Figure 4; 
typically, the number of F.IX-expressing cells was approximately 2- to 3-fold higher in 
theAAV-1–injected tissue.
Intramuscular injection of AAV-1 in immunocompetent mice triggers formation of antibody 
to the transgene product but not destruction of the transduced cells
Previously we have shown that intramuscular injection of AAV-2 vectors in 
immunocompetent mice results in formation of antibodies to hF.IX,13 but long-term 
persistence of and expression from the transduced cells and no evidence of cellular infiltrate 
at the injected site.19 This is consistent with a primarily T helper cell 2 (Th2)–driven 
response. Although the capsid sequences of AAV-1, AAV-2, and AAV-6 are highly 
conserved, one cannot assume that the characteristics of the immune response will be 
identical. We therefore examined immune responses to vector injection/ transgene 
Arruda et al. Page 5













expression in immunocompetent mice. In the first experiment, C57Bl/6 mice received an 
intramuscular injection of AAV-1–F.IX at a dose of 2 × 1010 vg per site (~4 × 1012 vg/kg). 
Animals were killed at 2 weeks and 4 weeks after injection, and injected muscle was excised 
and stained with hematoxylin and eosin (Figure 5). Sections showed no evidence of 
inflammatory infiltrate or destruction of muscle architecture. Examination of injected tissue 
at time points out to 12 weeks showed no evidence for loss of transduced cells.
In the immunofluorescent stains, the number of positive cells increases from week 2 to week 
4. Hematoxylin and eosin staining is remarkable for the absence of cellular infiltrates and 
the preservation of normal muscle architecture. In another experiment, C57Bl/6 mice with 
hemophilia B due to a large deletion in the F.IX gene20 were injected with AAV-1 at doses 
ranging from 4 × 1012 vg/kg to 1.6 × 1013 vg/kg. These doses resulted in circulating levels 
of F.IX ranging from 20 ng/mL to 110 ng/mL at 2 weeks following by undetectable levels at 
week 4 due to antibody formation to F.IX documented in all mice by Western blot and by 
ELISA for F.IX-specific IgG (Figure 6B,D). These were inhibitory antibodies as 
documented by Bethesda titers ranging from 0.5 to 13.7 Bethesda units (BU) (Figure 6C). 
Antibodies generally appeared approximately 2 weeks after injection and persisted for 
periods up to 8 weeks after injection. Following this, antibodies disappeared and F.IX was 
again detectable in the circulation at levels ranging from 200 ng/mL to 3000 ng/mL (Figure 
6A).
A third group of animals (n = 3) was injected with a lower vector dose (6.5 × 1011 vg/kg). In 
this group, transient circulating F.IX levels of 20 ng/mL to 25 ng/mL were detected up to 
week 3. By week 4, antibody to F.IX was detected in all animals. In contrast to animals 
injected with higher vector doses, where antibodies to F.IX were decreasing by week 8 and 
had disappeared altogether by week 12 (Figure 6B), in the low-dose group, levels of 
antibodies to F.IX remained stable for the duration of the experiment (12 weeks) with no 
evidence of diminution (Figure 6E).
Intramuscular injection ofAAV-1–cF.IX in hemophilic dogs results in inhibitor formation at 
lower doses than those that trigger inhibitor formation following AAV-2 intramuscular 
injection
Previous studies in a hemophilia B model showed that risk of inhibitor formation following 
intramuscular injection of AAV-2 vector rises as the dose of vector rises.11 Animals that 
received doses up to 3.4 × 1012 vg/kg did not form inhibitory antibodies, whereas 2 out of 3 
animals injected at doses equal to or higher than 8.5 × 1012 vg/kg developed inhibitors 
(Table 4). Moreover, the vector dose per site also seemed to play a role, since, of 3 animals 
that received comparable doses (8 × 1012 vg/kg), the dog (B14) that received a high dose per 
site (1.2 × 1013 vg/site) formed a long-lasting high titer inhibitory antibody, whereas the 2 
dogs that received a lower dose per site (2 × 1012 vg/site) either failed to form an inhibitor or 
developed only a transient low titer inhibitor. Analysis of immunoglobulin subclasses in the 
earlier study showed that noninhibitory antibodies consisted of IgG2 only, whereas animals 
with inhibitory antibodies showed both IgG1 and IgG2. Whether the dose dependence of 
risk of inhibitor formation resulted from increasing levels of F.IX antigen, higher numbers 
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of viral particles, higher levels of a contaminant that acted as an adjuvant, or some 
combination of these factors, was not clear.
The higher expression levels of the AAV-1 vectors provided a means of examining which of 
these factors contributed to inhibitor formation. We injected a hemophilia B dog (E35) at 
intramuscular sites with AAV-1–cF.IX at a dose of 1 × 1012 vg/kg, 5 × 1011 vg per site. In 
terms of the dose per kilogram, this was 8-fold lower than the dose per kilogram associated 
with inhibitor formation with AAV-2 vectors, and 4-fold lower than the dose per site. 
However, as shown in Figure 7, even at these doses, which never trigger inhibitory antibody 
formation with AAV-2–F.IX, the injected animal formed inhibitory antibodies starting about 
5 weeks after vector injection. As shown in Figure 7A, the cF.IX level peaked at 87 ng/mL 
(1.7% normal circulating level in humans) at 2 weeks after injection. This rise in F.IX levels 
was accompanied by a reduction in the WBCT (Figure 7B). As the inhibitor developed, 
though (Figure 7C), F.IX was no longer detectable in the circulation and the WBCT returned 
to baseline (> 60 minutes). This inhibitor rose to a peak of 15 BUs and persisted in the range 
of 8 BU to 10 BU for 250 days before falling to a lower titer. Determination of 
immunoglobulin subclasses again revealed high levels of IgG2 initially followed by 
development of IgG1 antibodies concomitant with the appearance of the inhibitor.
Clinical laboratory studies including muscle enzymes and liver function tests showed that 
intramuscular injection of AAV-1 was not associated with systemic or local toxicity at early 
times after administration. The development of an inhibitory antibody was heralded by a rise 
in the WBCT (from 12 minutes at day 10 to 27.5 minutes at day 15). We attempted to 
address this by instituting immunosuppressive therapy with intravenous cyclophosphamide 
(200 mg/m2–250 mg/m2) administered weekly from day 15 to day 50 after vector injection. 
However, this maneuver did not result in any significant diminution of inhibitor titer, and 
the animal experienced a life-threatening retropharyngeal bleed 10 months after injection, 
which required euthanasia.
Dose reduction and transient immunosuppression at the time of vector administration 
delay but do not block the formation of inhibitory antibodies
Because our previous studies in dogs with hemophilia B have shown that the risk of 
inhibitor formation increased with dose per kilogram and dose per site, we wished to 
determine whether a reduction in dose would prevent the formation of inhibitory antibodies. 
Our earlier studies had also shown that transient immunosuppression with 
cyclophosphamide could prevent inhibitor formation, both in the missense mutation dogs 
treated at higher doses11 and in nonsense mutation dogs.21 We therefore transiently 
immunosuppressed a second animal, E57, (cyclophosphamide 200 mg/m2–250 mg/m2 one 
day before injection and weekly thereafter for a total of 6 infusions) treated at a vector dose 
of 2.4 × 1011 vg/kg (4-fold reduction compared with the first dog) and a dose per site of 6.7 
× 1010 vg/site (8-fold reduction compared with E35). Initial results showed a gradual 
increase in cF.IX levels to a maximum of 104 ng/mL (Figure 8A). For comparison, a similar 
dose of AAV-2–F.IX (1.3 × 1011 vg/kg) in dog B45 resulted in circulating levels of only 2 
ng/mL to 3 ng/mL, so that at low doses, AAV-1 appeared approximately 20-fold better than 
AAV-2 (Table 4). The combination of dose reduction and transient immunosuppression 
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initially appeared successful, since there was no evidence of inhibitory antibody formation. 
Three weeks after cyclophosphamide was stopped, the animal developed a bleed in the 
hindlimb and was treated with canine plasma. After the plasma transfusion, an inhibitor was 
detected, initially at a titer of 2 BU and rising to approximately 4 BU. The inhibitor titer 
subsequently fell but rose again after a second plasma transfusion (Figure 8B–D). Time-
course analysis of the appearance of antibodies to F.IX shows that both IgG1 and IgG2 had 
appeared before the first plasma transfusion (Figure 8D). Of note, both dogs were never 
exposed to plasma-derived cF.IX prior to AAV vector injection.
Discussion
AAV-2–mediated gene transfer to murine skeletal muscle resulted in circulating F.IX levels 
of 250 ng/mL to 350 ng/mL at doses of approximately 1 × 1013 vg/kg13; a similar study in 
hemophilic dogs yielded circulating levels of 70 ng/mL at a comparable dose.10 A phase 1 
safety study of intramuscular injection of an AAV-2 vector in humans with hemophilia B 
showed an excellent safety profile and strong evidence for gene transfer and expression on 
muscle biopsy2 but circulating levels of F.IX that were generally subtherapeutic (< 1%) at 
the doses tested (up to ~2 × 1012 vg/kg). Studies in hemophilic dogs had shown that the risk 
of inhibitory antibody formation rose with increasing doses of vector per site, so that dose 
escalation in the human study required ever-increasing numbers of injection sites. To scale 
up 3- to 5-fold in dose from 2 × 1012 vg/kg (to reach doses that were therapeutic in mice and 
dogs) would have required about 300 injection sites, which did not seem clinically feasible. 
Since published studies4,6 documented higher levels of transgene expression using an 
AAV-1 vector in murine skeletal muscle, we sought to determine whether these results 
could be extended to dogs with hemophilia B. We recognized at the outset that immune 
responses to the transgene product were likely to be a major consideration and we therefore 
assessed these responses as a part of our analysis.
Our study shows that, in both small and large animal models, AAV-1 results in higher levels 
of transgene expression compared with AAV-2 vectors. Although experiments in tissue 
culture documented that F.IX expression was generally higher with AAV-2 vectors 
compared with AAV-1, the opposite result was seen in immunodeficient mice, where F.IX 
levels were 10- to 20-fold higher with AAV-1 and AAV-6 vectors injected intramuscularly. 
This failure of experiments in tissue culture to predict relative levels of expression in vivo 
has been documented for a number of viral vectors, and the observation underscores the fact 
that tissue-culture data must be interpreted with caution in this setting. Our data on the 
relative efficacy of AAV-1– compared with AAV-2– derived vectors in mice addresses a 
point of controversy in the field. An initial report by Xiao et al6 documented 2- to 10-fold 
higher circulating levels of transgene products (erythropoietin and α1-antitrypsin) in mice 
injected with 2 × 1012 vg/kg of AAV-1 versus AAV-2 vectors, whereas a subsequent report 
by Chao et al4 reported 500- to 1000-fold higher levels of cF.IX in mice injected with 
AAV-1 versus AAV-2 at doses of approximately 1 × 1013 vg/kg. Our results were much 
closer to those of Xiao et al with a 10- to 20-fold increase in circulating levels of hF.IX in 
mice over a range of doses from 2 × 1011 vg/kg to 4 × 1012 vg/kg. Our results are also 
similar across species, since we observed a comparable dose advantage for AAV-1 in the 
hemophilic dog model. This is best appreciated by comparing doses and circulating levels in 
Arruda et al. Page 8













E57 to results in animals injected with AAV-2 cF.IX vectors that used the same gene 
expression cassette and differed only in the capsid gene sequences in the AAV helper 
plasmid. Thus, compared with previously published results in animal D32,11 injected with 
5.6 × 1012 vg/kg AAV-2 resulting in circulating levels of 40 ng/mL, AAV-1 was 58-fold 
better, whereas compared with dog B85,10 which received 8.5 × 1012 vg/kg and achieved 
circulating levels of 70 ng/mL, AAV-1 was 53-fold better (Table 4). One can argue that the 
comparison to D32 is more valid, since both D32 and E57 were treated with identical 
regimens of cyclophosphamide, but the similarity of results with either D32 or B85 suggests 
that the effect of the cyclophosphamide at the doses administered had a minimal effect on 
transduction levels. (Note that comparisons to the dog that received a higher dose of AAV-1 
[E35] are not possible, since this animal developed an inhibitory antibody before reaching a 
plateau level of F.IX).
The superior performance of AAV-1 compared with AAV-2 in skeletal muscle is at least 
partly due to improved transduction as reflected by a higher gene copy number and higher 
numbers of cells transduced. Thus, analysis of mice injected with equivalent doses of 
AAV-1 and AAV-2 (dose of ~4 × 1012 vg/kg, 2 × 1010 vg per site) showed that both gene 
copy number and total number of cells transduced were approximately 2- to 3-fold higher 
for AAV-1. If the vector gains entry to twice as many cells, then the increase in gene copy 
number is predictable assuming similar efficiency of conversion to a double-stranded form 
and stabilization of vector sequences. Yet a higher number of transduced cells cannot alone 
account for the improved performance of AAV-1, since at these doses circulating levels of 
F.IX are 20-fold higher in the AAV-1– injected mice. This suggests that there is a higher 
level of expression per transduced cell, or that there is production of F.IX in many more 
cells at levels sufficiently low that they are not readily identified as positive on 
immunofluoresence staining. More data are required to resolve this point, since it is not clear 
what fraction of vector DNA detected on Southern blot is transcriptionally active.
The major complication of the current therapy for hemophilia (intravenous infusion of 
clotting factors) is development of inhibitory antibodies. A wealth of data in hemophilic 
mouse and dog models demonstrates that inhibitors also arise in the context of gene transfer 
for hemophilia.10,11,21 Some of the factors that influence the risk of inhibitor formation in 
the setting of gene transfer include, in addition to the underlying mutation, the vector 
itself,19 the route of administration, the presence or absence of a tissue-specific promoter,22 
and the dose. A complex interplay among these factors may control the eventual outcome, 
so that, for example, an innate immune response to a virally derived vector may promote an 
adaptive immune response to the transgene product.
Our previous studies have shown that, in the setting of an F.IX-expressing AAV-2 vector 
delivered to skeletal muscle in hemophilic dogs, as the dose of vector increases the 
likelihood of inhibitor formation also increases, with the dose per site being one of the 
strongest predictors of inhibitor formation.11 One of the complicating factors in analysis of 
the immune response in gene transfer is the multicomponent nature of viral vectors. Thus, as 
the dose per site is raised, the host is responding to at least 3 factors: (1) an increase in the 
total number of viral particles; (2) an increase in the total amount of transgene product 
synthesized locally; and (3) an increase in the total amount of any contaminant in the 
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preparation. The higher efficacy ofAAV-1 allowed us to distinguish among these 
possibilities experimentally, since one can produce similar amounts of circulating F.IX using 
a much lower dose of vector. If one compares dog D32 (injected with AAV-2) with E57 
(injected with AAV-1), E57 received a 30-fold lower dose per site and a 20-fold lower dose 
per kilogram. Thus the total number of vector particles and the total amount of any 
contaminant were considerably reduced in E57, yet E57 developed a long-lasting inhibitory 
antibody, whereas D32 did not. (Note that both dogs were treated with identical transient 
immunosuppressive regimens at the time of vector injection.) Similarly, if E57 is compared 
with D31, a dog that also received AAV-2, the dose per site was again 30-fold lower in E57 
and the dose per kilogram was 30- to 40-fold lower, yet E57 developed a long-lasting 
inhibitor whereas D31 did not. These data suggest that it is the amount of transgene product 
(antigen) synthesized locally that is the major factor promoting development of a harmful 
immune response. This conclusion is consistent with a body of data in the vaccine literature 
that correlates amount of antigen delivered to an intramuscular site with strength of immune 
response.23
The experiments in immunocompetent hemophilic mice are of particular interest. These 
mice were injected with AAV-1 at doses ranging from 6.5 × 1011 vg/kg to 1.6 × 1013 vg/kg. 
At a dose of 6.5 × 1011 vg/kg, mice developed antibodies to F.IX that persisted for the 
duration of the experiment. At higher doses, mice initially developed inhibitory antibodies, 
but these disappeared over time, yielding very high plateau circulating levels of F.IX, in the 
range of 200 ng/mL to 3000 ng/mL. These findings are consistent with a model proposed by 
Zinkernagel,23 in which antigens that enter the secondary lymphoid organs in large amounts 
for a prolonged period induce and then delete reactive T cells. In this model, the 
localization, dose, and duration of antigen persistence are the crucial determinants of 
whether immune reactivity develops, with low doses of antigen being ignored 
immunologically, very high doses resulting in induction and then deletion of reactive T 
cells, and doses between these inducing an effective immune response. Zinkernagel’s model 
provides a framework for interpreting the experiments presented here as well as our earlier 
experiments in which AAV-2 was used to effect gene transfer into skeletal muscle in 
hemophilic dogs and humans. Thus, AAV-2–mediated gene transfer to skeletal muscle 
failed to trigger an immune response to the transgene product at low doses (as seen in the 
first group of dogs injected,10 and in the human subjects injected2), whereas injection of 
hemophilic mice or dogs with AAV-1, resulting in higher circulating levels of F.IX 
(antigen), allows development of an immune response (mice injected at 6.5 × 1011 vg/kg; 
dogs injected at 2.4 × 1011 vg/kg-10 × 1011 vg/kg). At still higher doses (as seen in the 
hemophilic mice reported here), resulting in very high antigen levels, an immune response is 
induced and then lost, presumably because the reactive T cells have been deleted. Although 
the model is consistent with the data in hand, additional experimental data will be required 
to confirm or refute this hypothesis.
In summary, AAV-1 results in superior transduction of skeletal muscle compared with 
AAV-2, in dogs as well as in mice. In this initial report of results with AAV-1 in large 
animals, we noted a similar fold increase in circulating levels of the transgene product, F.IX, 
in mice and in hemophilic dogs. This increase, on the order of 10- to 50-fold, is consistent 
with the first report in mice,6 but is considerably less than a later report in mice.4 For 
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AAV-2, experiments in a wide range of animals, including mice, rats, rabbits, dogs, 
nonhuman primates, and humans showed that the vector had similar transduction 
characteristics in skeletal muscle regardless of species. More work will be required to 
determine whether the same is true for AAV-1, but these initial results suggest that this 
vector too may have similar characteristics in a variety of species. The higher efficacy of 
AAV-1 is associated with an increase in gene copy number and a higher number of 
transduced cells, although these factors alone are not adequate to account for the higher 
levels of expression. Finally, the data presented here in immunocompetent hemophilic mice 
and in hemophilic dogs demonstrate that gene delivery by AAV-1 to skeletal muscle can 
evoke an immune response to the transgene product. The data in mice, where the inhibitory 
antibodies to F.IX ultimately disappeared, suggest that higher doses of vector, resulting in 
higher circulating levels of F.IX, may eventually tolerize the animal to the transgene 
product, but more extensive experimental analysis will be required to determine if this 
observation in mice can be extended to larger, outbred models of hemophilia.
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Figure 1. Constructs used in vector preparation
(A) Helper plasmids contain rep gene sequences fromAAV-2 and cap gene sequences 
fromAAV-2,AAV-1, andAAV-6 respectively. (B) The canine transgene cassette contains 
the cF.IX cDNA, the human β-globin intron 1, the CMV enhancer/promoter, and the human 
growth hormone polyadenylation signal, flanked by the AAV-2 inverted terminal repeats. 
The human transgene cassette contains the human F.IX cDNA interrupted by a 1.4-kb 
fragment of hF.IX intron 1, the CMV enhancer/promoter, and the SV40 polyadenylation 
signal, also flanked by the AAV-2 inverted terminal repeats.
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Figure 2. Time course of hF.IX expression in C57Bl/6 CD4 knockout mice
Mice were injected at 2 × 1011 vg/kg at 4 intramuscular sites in the hindlimbs. Each line 
represents average values for the cohort (n = 4 mice). Circles represent mice injected with 
AAV-6–F.IX vector; triangles, mice injected with AAV-1–F.IX; squares, mice injected with 
AAV-2–F.IX.
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Figure 3. Gene copy number in AAV-injected muscle tissue
(A) Southern blot analysis of genomic DNA extracted from murine skeletal muscle injected 
with AAV vectors. The first 3 lanes are from mice injected with AAV-1–F.IX at the doses 
listed beneath each lane; the next 3 lanes are from mice injected with AAV-2–F.IX. Copy 
number standards were prepared by adding 10, 100, or 1000 pg plasmid to 20 µg murine 
genomic DNA.
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Figure 4. Immunofluorescent staining for hF.IX in AAV-injected mouse muscle
Animals were injected in the hindlimbs with 4 × 1012 vg/kg AAV-1 or AAV-2, divided 
equally among 4 injection sites. Twelve weeks later mice were killed and injected muscle 
was resected for immunofluorescent staining. Positive cells were scored by observers 
blinded to vector type. Representative sections from the quadriceps are shown for AAV-1– 
and AAV-2–injected muscle; average percent of positive cells was 54% for AAV-1, 22% for 
AAV-2.
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Figure 5. Paired immunofluorescent and hemotoxylin and eosin staining of AAV-1–injected 
murine muscle at early time points after injection
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Figure 6. Human F.IX expression and anti–F.IX antibody measurements as a function of dose 
and time in AAV-1–injected immunocompetent hemophilic mice
C57Bl/6 hemophilia B mice were injected at a high (1.6 × 1013 vg/kg, n = 5), medium (4 × 
1012 vg/kg, n = 2), or low (6.5 × 1011 vg/kg, n = 3) dose at intramuscular sites. Panels A–D 
refer to medium- and high-dose cohorts, panel E to low-dose cohort. Each line represents 
one mouse. (A) Human F.IX levels were determined by ELISA. Levels in high-dose animals 
range from 300 ng/mL to 2200 ng/mL at 8 weeks, with levels of approximately 100 ng/mL 
at the same time point in medium-dose animals. After the initial lag, F.IX levels remain 
stable for the duration of the experiment. (B) Anti–F.IX-specific IgG1 antibodies. These 
were detected in all animals, peaked at 2 to 4 weeks after injection, markedly decreased by 8 
weeks, and disappeared by 12 weeks after injection. (C) Bethesda titers. Inhibitory antibody 
is first detected at 2 weeks after injection, reaches a maximum at 4 weeks, then gradually 
diminishes. (D) Western blot to detect anti–F.IX antibody. Lanes 1 to 5 contain serum from 
the mice treated at a high dose, lanes 6 to 7 conatin serum from mice treated at a lower dose. 
At the 4-week time point, antibody was detected in 5 of 7 mice. At the 8-week time point it 
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was detected in only 2 of 7 mice. (E) Left panel represents hF.IX levels determined by 
ELISA. Center and right panels represent antibodies to F.IX detected in all 3 mice by 
specific IgG to F.IX or by Bethesda assay, respectively. *Denotes the death of one animal 
after week 8.
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Figure 7. Coagulation testing and antibody studies in dog E35
(A) Canine F.IX antigen levels as a function of time after injection. F.IX level peaked 2 
weeks after injection and rapidly declined to undetectable. Arrows denote time points at 
which cyclophosphamide was administered. (B) WBCT as a function of time after injection. 
The WBCT fell into the normal range by day 6 and began to prolong again by day 15. By 
day 23 it had returned to the baseline of more than 60 minutes. (C) Bethesda titer as a 
function of time. An inhibitory antibody of 8.2 BU was first detected at day 27, and 
persisted for the remainder of the animal’s lifespan. (D) Anti–F.IX antibody measured by 
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subclass as a function of time. IgG2 was first detected at high levels (2225 ng/mL) on day 
15 after vector injection, prior to appearance of inhibitory antibody or to infusion of canine 
plasma. IgG1 rose gradually beginning about 35 days after vector injection and continued to 
rise throughout the course of the experiment.
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Figure 8. Coagulation testing and antibody studies in dog E57
(A) Canine F.IX antigen levels as a function of time after injection. Arrows denote time 
points at which cyclophosphamide was administered; asterisks denote infusions of canine 
plasma. F.IX level peaked 55 days after injection and fell rapidly after cyclophosphamide 
was discontinued. (B) WBCT as a function of time after injection. The WBCT fell to the 
normal range about 1 week after vector injection. Levels remained reduced into or near the 
normal range until approximately day 70 when they were again prolonged. (C) Bethesda 
titer as a function of time after injection. Bethesda titer was undetectable until day 77. The 
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titer was initially low but subsequently rose to approximately 8 BU. (D) Anti–F.IX antibody 
subclasses as a function of time. Both subclasses remain at baseline through the duration of 
cyclophosphamide therapy, but IgG1 rises rapidly, and IgG2 more slowly, after 
cyclophosphamide discontinuation.
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Table 1
F.IX levels in the conditioned medium from murine C2C12 cells transduced with AAV-CMV-F.IX vectors at 
a range of multiplicity of infection










  1 000 3 ± 1 12 ± 2.6 4
  5 000 19 ± 4 60 ± 13 3
  20 000 29 ± 10 108 ± 37 3.7
  40 000 36 ± 4.5 129 ± 40 3.5
Differentiated C2C12 cells
  1 000 33 ± 10 107 ± 47 3.2
  5 000 63 ± 29 126 ± 29.4 2
  20 000 103 ± 12 208 ± 30 2
  40 000 115 ± 8 247 ± 58 2
Fold range difference 3 to 10 2 to 15
Over prolonged periods and over a broad dose range, AAV-1– and AAV-6–based vectors result in higher levels of expression of a F.IX transgene 
compared with AAV-2 vectors in immunodeficient mice.
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Table 2
Circulating F.IX levels 8 weeks after intramuscular injection of AAV vectors in mice
Vector dose, vg/kg AAV-1 AAV-2 Fold difference
2 × 1011 198 ± 96 19 ± 3 10.4
1 × 1012 436 ± 79 20 ± 5 21.8
4 × 1012 1115 ± 120 53 ± 10 21.0
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